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Array-CGH analysis indicates a high prevalence of genomic 
rearrangements in Holoprosencephaly: an updated map of 
HPE candidate loci. 
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ABSTRACT  
Holoprosencephaly (HPE) is the most frequent congenital malformation of the brain. 
Aetiology includes karyotype anomalies, environmental factors and genic forms that 
can be syndromic or isolated. Non-random structural chromosomal anomalies 
previously compiled from chromosomal HPE predicted at least 12 different HPE loci. 
To date, eight HPE genes have been identified from recurrent chromosomal 
rearrangements or from the sequencing of genes from Nodal and SHH pathways.  
Our cohort of isolated HPE presents a high genetic heterogeneity. Point mutations 
were found in SHH, ZIC2, SIX3 and TGIF genes in about 20% of cases (with 10% in 
SHH). Submicroscopic deletions in these same genes were found in 7.5% and 4.4% 
presented with other subtelomeric gain or losses. Consequently molecular basis of 
HPE remains unknown in 70% of our cohort. 
In order to detect new HPE candidate genes, we used array-CGH to refine the 
previous karyotype based HPE loci map. We analysed 111 HPE patients with high 
performance Agilent arrays made of 44K or 244K oligonucleotidic probes and found 
that 28 presented with submicroscopic anomalies involving known or new potential 
HPE loci located on different chromosomes but with poor redundancy. We observed 
14 isolated deletions, 9 isolated duplications and 5 associated genomic losses and 
gains. Compiling these new data with frequencies of deletions in known HPE genes 
and of subtelomeric anomalies, we give evidence that microrearrangements could be 
a major molecular mechanism in HPE. Additionally, this study opens new insights on 
HPE candidate genes identification giving an updated HPE candidate loci map. 
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INTRODUCTION 
 
Holoprosencephaly (HPE; MIM 236100) is the most common forebrain 
developmental anomaly in humans, resulting from a complete or partial failure of 
cleavage of the forebrain during development. The clinical spectrum ranges from 
alobar HPE (absent interhemispheric fissure) to semilobar (posterior midline 
separation) and lobar HPE (continuity only across the frontal cortex) generally 
associated with facial anomalies. HPE is a severe pathology, associated with mental 
retardation in all affected live newborns, with poor or symptomatic treatment (Cohen, 
2006). The genetic counselling in HPE families is very complex due to the extreme 
phenotypical variability, the genetic heterogeneity, and a high recurrence risk (13%) 
in apparently sporadic cases. Chronologically, non-random structural chromosomal 
anomalies previously compiled from chromosomal HPE predicted at least 12 different 
HPE loci, and out of these 12 loci, eight genes have been really implicated in HPE 
with mutations found in isolated HPE: Sonic hedgehog (SHH; 7q36; HPE3)(Belloni, et 
al., 1996; Roessler, et al., 1996)], ZIC2 (13q32; HPE5)(Brown, et al., 1998), SIX3 
(2p21; HPE2)(Wallis and Muenke, 1999), TGIF (18p11.3; HPE4)(Gripp, et al., 2000), 
PATCHED1 (9q22)(Ming and Muenke, 2002), TDGF1 (3p21.31)(de la Cruz, et al., 
2002), FAST1 (8q34) (Ouspenskaia, et al., 2002) and GLI2 (2q24)(Roessler and 
Muenke, 2003). In total, these actors play a role either in the SHH pathway, or in the 
Nodal/Transforming Growth Factor beta (TGFβ) pathway, or as transcription factors. 
Point mutations in the four major genes, SHH, ZIC2, SIX3 and TGIF, were identified 
in 20% of our HPE patients. Among these genes, SHH appears to be the major one 
accounting for 50% of the identified mutations (Dubourg, et al., 2004).  
Animal studies and rare human cases showed that double heterozygous mutations 
could be involved in HPE phenotype, introducing the multi-hit hypothesis in this 
developmental disorder (Ming and Muenke, 2002). This hypothesis helped in the 
understanding of the variable penetrance of familial mutations in the disease and led 
us to systematically screen the four genes, even if one mutation was initially found in 
the first sequenced gene. Additional work is focusing on environmental factors 
including low cholesterol levels (Edison, et al., 2007). 
Since 2003, we also screened these genes for microrearrangements and proved for 
the first time the implication of gene deletions in 7.5% in holoprosencephaly (3.2% in 
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SHH, 2% in ZIC2, 1.6% in SIX3 and 0.65% in TGIF) (Bendavid, et al., 2006a; 
Bendavid, et al., 2006b). When comparing the combined mutation and deletion 
results observed in the foetus cohort and in the live-born children, the total 
proportions of gene anomalies are close (28% and 24% respectively), but the rate of 
point mutations is much higher in live born children than in foetuses (23% versus 
14%) whereas submicroscopic deletions, which represent gross alterations, occur 
more frequently in foetuses (10% versus 5%) who generally have a more severe 
phenotype.  
Because of the HPE clinical and genetic heterogeneity, and the lack of informative 
families, a classical positional cloning strategy based on genome wide scan is not 
possible. Consequently, we were led to develop a strategy based on molecular 
biology and cytogenetics to identify candidate regions and thus candidate genes. 
This approach will complete the initial karyotype based study of recurrent 
chromosomal abnormalities which led to the identification of the first HPE genes 
(Belloni, et al., 1996) and HPE loci map (Roessler and Muenke, 1998). 
After screening of microdeletions or mutations in known HPE genes with 
QMPSF/MLPA or DHPLC plus sequencing respectively, we searched for 
submicroscopic rearrangements in subtelomeric chromosomal regions using the 
Multiplex Ligation Probe Amplification (MLPA) method (Hogervorst, et al., 2003). 
Indeed, subtelomeric aberrations were detected in 4,4% of our HPE patients with no 
known anomaly, showing either a single anomaly or an association between a 
deletion and a gain, these rearrangements were very heterogeneous, encompassing 
10 different subtelomeric regions. Some targeted regions known to be implicated in 
HPE (7q encompassing the SHH gene, 18p encompassing the TGIF gene, 21q 
including a candidate gene, LSS (Lanosterol Synthase)), but also new regions (1p, 
5q, 7p, 8p, 9q, 17q, 18q and 22q) were identified. Several samples, mainly foetal 
ones, consisted of an association between a duplication and a deletion in two 
chromosomal subtelomeres like (dup7pter; del7qter) or (dup20pter; del21qter). 
Moreover, rearrangements presented by foetuses generally implied known HPE loci, 
while those observed in live children encompassed regions not previously described 
(Bendavid, et al., 2007). But, even if we compile these large deletions, point 
mutations and deletions in the known genes, the combined rate of patients with 
identified molecular basis only reaches 30%, so more than 70% of the cases remain 
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unexplained, suggesting the involvement of many other genes in HPE (Dubourg, et 
al., 2007) and/or non genetic factors. 
The previous data showed the growing importance of microrearrangements in a 
complex genetic disease where mutations in the different genes have a variable 
penetrance and may need a second genetic event to give the disease. In order to 
identify new candidate loci and thus novel candidate genes, we decided to perform a 
genome wide screening for submicroscopic anomalies on isolated HPE patients, 
using Agilent array-CGH technology. We first tested the technique on 10 patients with 
known alterations in SHH, TGIF, ZIC2, SIX3 or subtelomeres in order to better define 
the size of the rearrangement and the breakpoints. Then 111 samples (64 fetuses 
and 47 live-born children), with no known karyotypes alterations, were hybridized. We 
chose these patients with no regard to their mutational status for the main HPE 
genes, resulting in that 18% of this group were carrying a mutation.  
Confirming the growing importance of micro rearrangements, this study showed up 
an impressive rate of 28 patients among 111 with submicroscopic chromosomal 
anomalies. These defects involved known or new potential HPE loci located on 
different chromosomes but with poor redundancy. Added to the previous 
microdeletion findings in known HPE genes and subtelomeres, our data showed that 
microrearrangements could be the major molecular mechanism in HPE and strongly 
reinforce the multigenic origin in this developmental disorder.  
MATERIAL AND METHODS 
 
Patients and controls 
 
The cohort consisted in 9 patients presenting with a known deletion already detected 
by qPCR or QMPSF in HPE genes (SHH, TGIF, ZIC2 and SIX3) or telomeric 
rearrangements shown by MLPA experiments and 111 HPE patients (64 fetuses and 
47 live-born children) with normal karyotype. Out of this whole cohort, all foetuses 
had severe HPE (central nervous system (CNS) findings consistent with HPE) 
whereas 15 live-borns had severe HPE and 32 had a spectrum of HPE microsigns 
(midline defect without cerebral malformation, including facial clefting, single central 
maxillary incisor, hypotelorism). 
Page 5 of 24
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Twenty patients with already known point mutations in the four HPE genes were also 
included, 20 of them with an inherited mutation and a severe phenotype whereas the 
transmitting parent had a microform.  
For only 21 cases with positive CGH result, we had both maternal and paternal DNA 
that could be investigated by array-CGH, MLPA or quantitative PCR to confirm de 
novo alterations. 
 
In order to simplify the interpretation of the results and better characterize CNVs, we 
used genomic DNA from one well-characterized normal male 46,XY and 1 well-
characterized normal female 46,XX as control. These two controls were regular blood 
donors that gave consent (to Etablissement Français du Sang) to use anonymously 
their DNA for diagnosis or research purposes. 
 
This study was approved by the Institutional Review Board, and parents of all 
participants gave their informed consent. 
 
Comparative Genomic Hybridization study 
 
Briefly, for live-born children, genomic DNA was extracted from peripheral whole 
blood by the Flexigene DNA kit from QIAGEN. For foetuses, DNA was extracted from 
tissues or cultured amniotic cells, using the QIAamp DNA minikit from QIAGEN. DNA 
concentration was determined using a NanoDrop Spectrophotometer (NanoDrop 
Technologies, Inc., Wilmington, DE). 
 
Array-CGH analysis can be hampered by the large DNA input requirement: a 
minimum of 0.5 µg per sample are needed to process one array-CGH. Most of our 
samples were extracted from foetuses, and only a small amount of DNA is often 
available. So, when necessary, DNA samples were amplified using a whole genome 
amplification method. In this case, control DNA was also amplified in order not to co-
hybridize a native DNA from a control with an amplified DNA from a patient. 
 
DNA amplification 
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DNA samples were amplified using the GenomePlex WGA kit (Sigma product code 
WGA2) according to the protocol provided by Sigma. The amount of DNA input into 
WGA reactions was 50 ng. 
 
Array-CGH  
Array-CGH was performed using the Agilent Human Genome Microarray Kit 44A and 
244A (Agilent Technologies, Santa Clara, CA, USA). These are high resolution 60-
mer oligonucleotide based microarrays containing 44,000 or 244,000 60-mers probes 
respectively, spanning coding and non-coding genomic sequences with median 
spacing of 24 kb and 7.4 kb respectively.  
When using native DNA, both patient and a sex-matched control’s DNAs were 
separately digested with both AluI and RsaI (Promega, Madison, WI, USA) for 2 h at 
37C°. Quality of digestion was controlled on a 1% agarose gel. 
When patient and control DNA were amplified digestion was not necessary as the 
WGA method already generates small fragments, and DNA was directly labelled after 
purification. 
 
Labelling 
DNA concentration was re-controlled using Qubit quantification method (Invitrogen, 
Carlsbad, CA, USA) in order to use the same DNA input for the patient and the 
control labelling. According to the protocol provided by Agilent (Protocol v4.0, June 
2006), the native digested or WGA2 amplified DNA were labelled by random priming 
using the Agilent “Genomic DNA Labelling Kit Plus”. Patient DNA and control DNA 
were labelled with Cy3-dUTP and Cy5-dUTP respectively. Labelled products were 
purified by Microcon YM-30 filters (Millipore, Billerica, MA, USA). Finally, patient and 
control DNAs were pooled based on equimolar DNA concentration measured with a 
Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Rockland, 
Delaware, USA). The mix was denaturated with Human Cot I DNA, and then 
hybridized on microarrays at 65°C for 24 to 48 h in a hybridization oven with a rotator 
rack. Washing steps and acetonitrile rinsing were performed according to the Agilent 
protocol in an ozone free area. Arrays were analysed using the Agilent scanner 
G2565BA and the Agilent Feature Extraction software version 9.1(CGH-v4_9.1 
protocol). The software removed outliers pixels and subtracted local background. 
Page 7 of 24
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Normalisation of the data was achieved by linear dye normalisation and log2 ratios of 
the dye-normalized signals were calculated.  
Bioinformatics 
Data were imported into Agilent CGHanalytics software version 3.4.27 for analysis. 
Identification of probes with a significant gain or loss was based on cut-off values of 
0.5 and -1 respectively. Based on CGHanalytics Quality control metrics (QCmetrics), 
the arrays included had a Derivative Log Ratio (DLR) spread score under 0,320. The 
DLR Spread metrics estimates the log ratio noise by calculating the spread of log 
ratio differences between consecutive probes along all chromosomes (Largo, et al., 
2007). DNA sequence information from the software was linked to the public UCSC 
database (Human Genome Browser, May 2004 Assembly: Hg18). We only 
conserved gains or losses that encompassed at least 3 consecutive spots on the 
array. We didn’t present in the result table the gains and losses corresponding to high 
frequency copy number variation (CNV). 
Based on a quality score for the arrays, we classified them in two groups so that to 
select arrays that could enter a transversal analysis using the Nexus Copy Number 
software (www.Biodiscovery.com). Patient CGH files extracted from Feature 
extraction were uploaded into the Nexus Copy Number software. This software also 
gives a quality score: all arrays with a score under 0.180 (corresponding to 0.320 in 
CGH analytics) allowed the transversal analysis without strong interfering 
background (that could generate false positive gains or losses). Using this 
transversal analysis, we compiled all array data and gave a graphic view of the 
combined results (aggregate) where the frequencies of anomalies were represented 
by histograms. This aggregate easily pointed out small redundant rearrangements 
that resulted either from frequent CNV either from one anomaly of the control DNA 
(mirror image in most of the patients). Finally, all gains or losses could be compared 
to CNV listed in the database (monthly updated from TCAG) and exported in Tables 
(Tables 1, 2 and 3) and Figure 1. 
The aim of this approach was to detect the redundancy of small regions and get a 
percentage value to compare with rare CNV frequencies for the same area when 
such CNV was already described in databases (TCAG human variation website: 
http://projects.tcag.ca/variation/). 
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RESULTS 
 
Search for CNVs in control DNA  
Male and female control DNAs were co-hybridized on a 244K microarray in order to 
better characterize copy number variants (CNV) that could be present even in these 
phenotypically normal individuals. 
Gains or losses observed in the two control genomic DNA were listed in order to be 
taken into account in the interpretation of patients’ array-CGH results (data not 
shown). 
 
Array-CGH analysis in patients 
120 patients (70 foetuses and 50 live-born children) were analysed either on a 44K or 
a 244K Agilent oligonucleotide arrays. 
Out of them, 9 presented with a known deletion already detected by qPCR or 
QMPSF on known genes (SHH, TGIF, ZIC2 and SIX3) or subtelomeric 
rearrangements shown by MLPA experiments. They were analysed on 44K arrays. 
A first cohort of 37 patients without any karyotypic alterations was also tested with 
44K agilent array-CGH and another cohort of 74 HPE patients was secondarily tested 
on 244K array-CGH as soon as this platform became commercially available. 
 Patients with known rearrangements 
Out of the 9 patients with known rearrangements analysed on 44K arrays, 7 were 
foetuses and 2 were live born children. 7 had severe HPE phenotype with alobar or 
semilobar form. These patients were known to present deletions in known genes like 
SHH, TGIF, ZIC2 and SIX3, but array-CGH analysis could give the size of the losses 
which ranged from 1 gene to 30Mb, and showed that 4 of them had also gain of 
genomic DNA. 
An overview of all imbalances is shown in Table 1.  
 Patients analysed on 44K arrays  
A first array-CGH analysis on 37 HPE patients was performed, using oligonucleotide 
44K Agilent® array. 19 cases were foetuses and 18 were live-born children. Sub 
microscopic chromosomal imbalances were detected in 9 (5 fetuses, 4 children) out 
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of them, 6 had an isolated deletions and 3 had duplications. The size of the 
imbalances ranged from 50 Kb to 16.9 Mb. (Table 2) 
 
 Patients analysed on 244K arrays  
Another cohort of 74 HPE (45 foetuses and 29 live-born children) was then analysed, 
using a higher resolution array (244K Agilent®). 
19 patients (12 fetuses, 7 children) out of 74 (26%) presented copy number variations 
not described in the CNV databases. These rearrangements are more frequently 
deletions as 12 patients had an isolated or associated loss. 11 patients had isolated 
or associated duplications. The size’s range of the imbalances is very large, from 300 
Kb to 16.5 Mb (Table 3). 
Nexus study 
Compiling 90 arrays (quality score below 0,180) in the Nexus study, the aggregate 
pointed out 2 regions overlapping known CNV but with a higher recurrence than what 
was reported in CNV databases. The first locus included two genes: MACROD2 and 
FLRT3 in 20p12.1. The second one included the gene TPPP in 5p15.3. 
DISCUSSION 
 
This study is the first series of HPE patients to be screened for chromosomal 
imbalances with high resolution oligonucleotide microarrays. In a total of 111 patients 
with normal karyotype, 28 were detected with chromosomal imbalances (25%). This 
unexpected high frequency, whatever the size, location and redundancy of the 
rearrangements, demonstrates that CGH is mandatory to detect submicroscopic 
molecular defects; consequently, adding these anomalies to the results of the classic 
diagnosis screening of isolated HPE, the rate of identified molecular defects could 
exceed for the first time 50% of cases. 
Methodology 
Control DNA 
We decided to use genomic DNA from one normal male 46,XY and one normal 
female 46,XX as controls. Indeed, it seemed to us that it was easier to validate the 
CNVs status of these two DNA samples and thus avoid false positive or negative 
results in our series. A similar strategy was chosen by Carter et al (Carter, 2007), 
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who selected NA15510, the source of fosmid library used to confirm genome 
assembly during the finishing of the human genome, and NA10851, a well 
characterized cell line DNA from the Hap-Map collection.  
CNV interference 
Results need to take into account the presence of potential copy number variants 
(CNV) present in the normal human genome. Indeed, the recent appreciation of 
widespread copy number variation in genomes of healthy subjects was a significant 
challenge for teams that wished to use array-CGH in order to correlate chromosomal 
imbalances and diagnosis of constitutional disorders. Public available databases that 
accumulate CNV data on hundreds of healthy individuals are now available. So we 
systematically compared our results to the Database of Genomic Variants (DGV) 
(http://projects.tcag.ca/variations), which in June 2008 contained 17641 CNVs entries 
from 49 different published studies using different array platforms and healthy human 
groups; most of these CNVs range from 40 to 100 kb (Carter, 2007). The referenced 
CNVs could account for over 20% of the human genome. Of course, this database 
should be considered with great caution, especially when these CNVs are reported 
only in a single individual out of hundreds what should definitely not deny any morbid 
role for such locus. Every month, new CNV data are described in the literature, so it 
is very difficult to consider all these data and to appreciate their accuracy. In our 
Nexus study, we pointed out two loci of interest based on a higher frequency than 
what could be found in CNV database: 
A first chromosomal region presented 4 gains and 5 losses in HPE patients, covering 
mostly 150 Kb, in 5p15.3. This redundant rearranged region contains a candidate 
gene, TPPP, expressed in adult brain and often described in Alzheimer papers. 
A second one was located in 20p. Indeed, among 110 HPE patients, 4 presented 
rearrangement at 20p12.1, 3 losses and 1 gain. These rearrangements spanned over 
several closed regions, all concerning one or several exons of MACROD2 gene 
(C20orf133) (Figure 1) whose embryonic expression pattern in the mouse orthologue 
is compatible with a role in holoprosencephaly (Maas, et al., 2007). This gene 
contains a nested gene in its third exon, called FLRT3, coding a fibronectin leucin-
rich repeat transmembrane protein, which could be a conserved Nodal target. 
Indeed, loss of function in the FLRT3 gene leads to defects in ventral closure, 
headfold fusion and definitive endoderm migration (Maretto, et al., 2008).  
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A deletion of MACROD2 was previously found in one patient with Kabuki syndrome 
(KS) ; sequencing of 19 other KS patients did not reveal any mutation in MACROD2 
discarding this gene as a unique candidate gene for KS (Maas, et al., 2007).  
To confirm that the rearrangements observed in our 4 patients were not benign CNV, 
the different database reporting these large-scale polymorphisms were investigated 
and unlike the Maas paper data, we could determine that they overlapped described 
CNVs. Moreover, Kuniba et al recently described the results of a deletion assay for 
the exon 5 in MACROD2 and a mutation analysis of MACROD2 and FLRT3 among 
43 patients with KS in Japan (Kuniba, et al., 2008). They also showed that 2 patients 
out of 18 presented copy number variations in this region, and concluded that 
MACROD2 and/or FLRT3 could not be the causative gene in most Japanese KS 
patients.  
These two papers and our own analysis demonstrate that one should be very 
cautious about the involvement of genes in diseases without an achieved CNV 
database to analyze the results.  
 
Minimal size to be considered 
Currently available data suggest using a DNA size cut-off for a positive result. To 
avoid listing many anomalies (small CNV or background noise related to one or two 
consecutive spots on the array), we chose that all data presented in tables must 
result from three consecutive co-deleted or co-duplicated probes on the 44K or 244K 
arrays to produce strong evidence of any genomic defect; consequently their 
respective resolution can be estimated to 48kb and 14.8kb respectively.  
This compromise is not perfect as this cut-off of 3 spots on the 44K array would have 
led us to discard a deletion located only on SIX3 gene (Table 1) and involving only 
one spot, if we had not been aware of its existence based on previous specific 
studies (Bendavid, et al., 2006a). 
 
Impact of array resolution 
We used the oligonucleotide 44K Agilent® arrays to test 37 HPE patients (19 
foetuses and 18 live-born children). Sub microscopic chromosomal imbalances were 
detected in 9 out of them (24%), 6 deletions and 4 duplications (Table 2). Another 
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cohort of 74 HPE (45 foetuses and 29 live-born children) was then analysed, using 
244K Agilent® arrays. 19 patients out of 74 (26 %) presented rearrangements. 
When using the high resolution arrays, the rate of detected rearrangements modestly 
raises (26% versus 24%). This suggests that the resolution of the 44K arrays could 
be sufficient for routine screening of HPE patients. On the opposite, the higher rate of 
small deletions detected by 244K needs more data compiling (based on Nexus 
software to point out the more frequent anomalies and exclude putative CNV). In 
routine diagnosis, the cost of the 244K array versus its modest raise of the detection 
rate could certainly limit the CGH approach to the 44K array. 
 
 
Patient’s results 
Identified loci were heterogeneous in size and poorly redundant, but 
large anomalies were preferentially found in fetuses 
Previous data suggested that deletions in known genes (SHH, SIX3, ZIC2 and TGIF) 
were more frequent in foetuses than in children, who, on the opposite, presented a 
higher rate of mutations (Bendavid, et al., 2006a; Bendavid, et al., 2006b). The 
present study corroborates this hypothesis as 17 chromosomal rearrangements were 
observed in foetuses (61%) versus 11 in children (39%).  
The structural variations observed in our cohort present a wide range of sizes.  
We first determined the precise size of rearrangements in samples known to be 
deleted for HPE genes (SHH, TGIF, SIX3 and ZIC2) by qPCR, QMPSF or MLPA or 
by high resolution karyotype (Table 1). The patient (N°8) with a deletion of TGIF in 
18p shown by quantitative PCR (Bendavid, et al., 2006a) had in fact a 10 Mb loss of 
telomeric genomic DNA. Deletions in 13q including ZIC2 ranged from 1.7 Mb to 30.7 
Mb, while those including SHH in 7q ranged from 3 Mb to 7 Mb. The severity of the 
phenotype seems to be correlated with the size of the deletion, if we consider that 
wider rearrangements are mostly found in foetuses with alobar or semi-lobar HPE, 
while the smaller ones (even concerning a single probe like the patient (N°1) with 
isolated SIX3 deletion) were preferentially observed in live-born children, with lobar 
HPE accompanied with minor signs. Nevertheless, phenotype/genotype correlation is 
not straight as children with typical HPE do not have a higher rate of rearrangements 
than children with minor signs.  
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Parental analysis 
In our series, out of 28 patients with gains or losses, both parents could be tested in 
21 cases (focusing on 26 rearrangements). The aim of this parental analysis was to 
further modulate the role of these rearrangements in phenotype onset based on their 
inheritance. 
Therefore, we postulated first that all anomalies found isolated (not associated  with a 
mutation) and that raised de novo in the proband would be the more likely to be 
involved in the phenotype. Second, all anomalies found isolated but inherited from 
one parent would be part from a genetic background and may only act with a variable  
penetrance or with an associated factor. Finally, if found associated with a mutation 
and inherited from one parent, the anomaly would more likely be a very minor 
modulator. 
In our series, 9 patients had at least one gain or loss inherited from one parent; 8 
were duplications whereas only 3 were deletions (patients N° 23, 30 and 32). In 6 
patients (N° 18, 21, 27, 30, 32 and 37), rearrangements were associated to 
mutations. Therefore, no definitive conclusion about the involvement of these 
different regions can be given. 
On the opposite, out of the 11 patients with de novo gains or losses, we had 9 
deletions and only 4 duplications.  8 involved known HPE loci: 2p (SIX3), 7qter 
(SHH), 13q (ZIC2), 18pter (TGIF), 20pter and 21qter. This reinforces the implication 
of loci like 20pter or 21qter in HPE but also gives new candidate loci with regions not 
previously involved in the disease: 1q, 6q, 7p, 10q, 14q and 17q. The 14q del was 
already reported by Kamnasaran et al in 2005 as a putative HPE loci (Kamnasaran, 
et al., 2005). The two overlapping 6q del are also particularly interesting as they 
mapped a new locus that appeared twice de novo. 
It’s worth noting that one patient (N°25) presents a SHH locus duplication. This could 
be associated with a SHH gain of function, what has never been described before in 
HPE. Nevertheless, this defect was also found in the mother (normal phenotype). 
SHH gains of function are usually associated with basocellular carcinoma that have 
not been described to date in this family. On another hand, this rearrangement may 
cause a SHH loss of function based on the modification of the chromatin 
environment. Further investigations on SHH expression in this family should be 
overtaken. 
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Update of HPE loci map 
The major aim of our research is to identify candidate regions, map them (Figure 2) 
and thus extract new HPE candidate genes. Because of the large number of non 
redundant loci found and the large number of genes covered, it was not relevant to 
list every candidate gene that could be hypothesized out of these regions. 
Nevertheless, our results are a milestone in further genetic research and diagnosis in 
HPE. Effectively, an important bioinformatics investigation on these regions can 
therefore be performed, based on gene networks and known functional studies 
results in order to prioritize the best candidate regions and genes out of our data. 
Today, only one region could be easily hypothesized as it showed a redundancy in 4 
patients who presented a deletion of about 100Kb without overlap with CNVs in the 
TCAG database to date. This region is located in 10p12.1 and contains a candidate 
gene, PATCHED3, belonging to the PATCHED family, receptor of SHH, one of the 
main HPE genes. Nevertheless, we could investigate the parents for one case (N°30) 
and the deletion was inherited from the father, knowing that furthermore the father 
also transmitted a SHH mutation. Another case (N°27) with no parental study also 
had an associated SHH mutation. Consequently, a role for PATCHED3 is 
questionable and it’s difficult to consider it as a strong modulator making the fetus 
phenotype worse than his father’s. 
 
CGH use in routine diagnosis 
For diagnosis, this study demonstrates that the CGHarray approach must be another 
part of the molecular routine so that to get as much potential markers of the disease 
as possible to help the genetic counseling. In our experience, this method has been 
very helpful in the identification of unbalanced subtelomeric anomalies (as MLPA for 
subtelomeres but with the advantage of determining the breakpoints in the same 
time) and led to identification of parental cryptic balanced translocations by FISH.  
Finally, this study also reinforces the multi-hit hypothesis showing 16 patients with 
associated gains and losses or rearrangements and mutations. The patients (with 
severe phenotype) with known mutations inherited from one parent (with mild 
phenotype) plus a gain and/or a loss are a strong example of what could be 
considered as a genetic background helping the mutation penetrance. 
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Conclusion 
This is the first study screening a large cohort of isolated HPE by CGHarray. Results 
demonstrated a high frequency of submicroscopic anomalies with yield of 25%. 
These anomalies are heterogeneous in size and poorly redundant, what give even 
more evidence of the multi and plurigenic origin of this developmental disorder. The 
map of these anomalies added to known candidate loci will certainly help to associate 
potential candidate genes from developmental research with the human disease. 
This study also demonstrates that CGH must be part of the molecular diagnosis 
algorithm to help clinicians to get more disease markers for the difficult HPE genetic 
counseling. 
 
 
Databases  
Database of Genomic Variants (http://projects.tcag.ca/variations), 
Human Genome Browser, (May 2004 Assembly: Hg18). 
Nexus Copy Number software (www.Biodiscovery.com) 
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Figure 1: Schematic view of the exons and introns of MACROD2 and FLRT3 genes. 
MACROD2 contains 17 exons and is 2057697 bp size. It contains in the third intron 
the FLRT3 gene. This three exons gene is 13628 bp in size. Red lines indicate 
deletion of patients, Green line indicate duplication. Positions of CNVs are 
represented by pink lines (updated in june 2008).      
 
 
Figure 2: This figure represents all chromosome ideograms  with: 1) in yellow, on the 
left of each ideogram, all related known HPE loci included in Roessler et al (1998) 
and 14q loci from Kamnasaran and al (2005) papers. 2) in green all gains found in 
our cohort 3) in red all losses found in our cohort. Gains and losses are associated 
with the patient numbers that can be found in tables 2, 3 and 4. 
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: Schematic view of the exons and introns of MACROD2 and FLRT3 genes. MACROD2 contains 17 exons and is 2057697 bp size. It contains in the third 
intron the FLRT3 gene. This three exons gene is 13628 bp in size. Red lines indicate deletion of patients, Green line indicate duplication. Positions of CNVs 
are represented by pink lines (updated in june 2008).  
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Table 1: CGH analysis in 9 patients with known defects 
 
Patient Phenotype F / C Sexe Anomalies Start-End size (Mb) sequencing 
1 lobar C   Del 2p 45022541-45025894  
Only six3 
gene 
  
2 lobar C M Del 5qter 177354922-ter 3,5   
  
      Dup 17q 70880633-ter 7,9   
3 alobar F   Dup 7pter 0-6167900 7  
  
      Del 7qter  152087784-ter 7   
4 semi lobar F F Del 7q 
154943585-
1578473434  3   
  
      Dup 8p 0-409876  0.4   
5 syndromic HPE F F Del 7qter 152232455-ter 6,2   
6 semi lobar F M Del 13q 98323528-100026969 1,7   
7 alobar F M Del 13q ter 83266096-ter 30,7   
8 semi lobar F M  Del 18pter  66272268-ter  10   
9 alobar F M Del 20p 0-8268492 8,2   
  cardiac anomalies     Dup 21q 35804023-ter 11   
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Table 2: Summary of copy number changes detected by 44K array CGH (short clinical 
description and associated mutations in HPE genes) 
 
Patient Phenotype F / C Sexe Anomalies Start-End taille (Mb) sequencing 
10 semi lobar F F Dup 1q  165319168-165662668 0,3   
  
      Dup 10q  59312961-60086986 0,8   
11 minor signs C M Del 6q 69637936-86100038 16,9   
12 Semi lobar F F Del 6q 155166802-ter 15,7   
13 semi lobar C M Dup 12p 26727022-27427780 0,8   
14 lobar, polymalformations F M Dup14q 49150663-49200220 0,05   
15 syndromic HPE C F Del 16p 29407325-30255748 0,85   
16 semi lobar F M Del 18q 62405035-63364892 1   
17 alobar F F Del 20p 18377837-23793823 5,4   
18 semi lobar C F Del 21q 19024763-20666763 1,6 Zic2 de novo 
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Table 3: Summary of copy number changes detected by 244K array CGH (short clinical 
description and associated mutations in HPE genes) 
 
Patient Phenotype F / C Sexe Anomalies Start-End Size (Mb) sequencing 
19 lobar C M Dup 1p 26866731-27930229 1,06   
20 minor signs C F Del 1p 61656706-77968936 16,4   
21 semi lobar F M Dup 3p 54969531-55519135 0,55 SHH paternal 
22 alobar F F Dup3q 101837302-101896892 0,6   
23 minor signs C F Del 7q 142530842-142603299 0,7   
  
      Dup 6p 13251543-13558381 0,3   
24 minor signs C M Del 6qter 165767853-ter 5,2   
  
      Dup 20pter 0-7967454 8   
25 semi lobar F M Dup 7q 154623987-155557785 0,93   
26 minor signs C F Dup 8q 98220486-98365015 0,15   
27 minor signs C M Del 10p  27656534-27753830 0,10 SHH 
28 lobar F M Del 10p 27645595-27754606 0,11   
29 alobar F F Del 10p 27645595-27754606 0,11   
30 lobar + familial form F M Del 10p 27645595-27754606 0,11 SHH paternal 
31 alobar F F Del 14q 29960612-46532138 16,5   
32 alobar F M Del 18p 0-602022 0,6   
  
      Dup 18p 1707459-1834111 0,13 Zic2 (de novo) 
33 semi lobar F M Del 19p 0-402006 0,4   
34 minor signs C F Dup 19p  0-1124473 1,1   
  
      Del 21q 44012487-ter 2,9   
35 semi lobar F F Del Xp 48145179-52507792 4,4   
36 minor signs F F DupXp 7542546-8091810 0,5   
37 alobar F M Dup Xp 2709755-2923910 0,3 2 in Zic2 
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Table 4:Study of inheritance in 21 probands (out of 31) whose both parents were 
available for analysis. Gene dosage was performed (QMPSF or MLPA or CGH) in the 
parents to check if the remaniement was inherited. Out of three patients with 
subtelomeric gain and loss, FISH was only performed in one case and confirmed a 
balanced translocation in one parent. 
 
  mutations remaniement 
Patient anomalies father mother father mother 
10 Dup 1q  No No No No 
  Dup 10q  No No No No 
1 Del 2p No No No No 
21 Dup 3p Yes no Yes No 
22 Dup3q No No Yes No 
23 Dup 6p No No No Yes 
  Del 7q No No No Yes 
11 Del 6q No No No No 
12 Del 6q No No No No 
3 Del 7qter No No No balanced 
  Dup 7pter No No No balanced 
25 Dup 7q No No No Yes 
26 Dup 8q No No No Yes 
30 Del 10p Yes No Yes No 
13 Dup 12p No No Yes No 
6 Del 13q No No No No 
7 Del 13q ter No No No No 
31 Del 14q No No No No 
2 Dup 17q No No No No 
32 Del 18p No No Yes No 
  Dup 18p No No Yes No 
8 Del 18pter No No No No 
9 Del 20p No No No No 
  Dup 21q No No No No 
18 Del 21q No No No No 
36 DupXp No No Yes No 
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